Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Burmester GR, Buttgereit F, Bernasconi C, Álvaro-Gracia JM, Castro N, Dougados M, Gabay C, van Laar JM, Nebesky JM, Pethoe-Schramm A, Salvarani C, Donath MY, John MR; SEMIRA collaborators. Burmester GR, et al. Among authors: pethoe schramm a. Lancet. 2020 Jul 25;396(10246):267-276. doi: 10.1016/S0140-6736(20)30636-X. Lancet. 2020. PMID: 32711802 Clinical Trial.
Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, Nomura A, Lacey S, Pei J, Reiss W, Pethoe-Schramm A, Mallalieu NL, Wallace T, Michalska M, Birnboeck H, Stubenrauch K, Genovese MC. Burmester GR, et al. Among authors: pethoe schramm a. Ann Rheum Dis. 2017 Jun;76(6):1078-1085. doi: 10.1136/annrheumdis-2016-210297. Epub 2016 Dec 22. Ann Rheum Dis. 2017. PMID: 28007755 Free article.
Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy.
Safy-Khan M, Jacobs JWG, de Hair MJH, Welsing PMJ, Edwardes MD, Teitsma XM, Luder Y, Devenport J, van Laar JM, Pethoe-Schramm A, Bijlsma JWJ. Safy-Khan M, et al. Among authors: pethoe schramm a. Ann Rheum Dis. 2020 Apr;79(4):460-463. doi: 10.1136/annrheumdis-2019-216537. Epub 2020 Feb 7. Ann Rheum Dis. 2020. PMID: 32033935
Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials.
Verhoeven MM, de Hair MJ, Tekstra J, Bijlsma JW, van Laar JM, Pethoe-Schramm A, Borm ME, Ter Borg EJ, Linn-Rasker SP, Teitsma XM, Lafeber FP, Jacobs JW, Welsing PM. Verhoeven MM, et al. Among authors: pethoe schramm a. Ann Rheum Dis. 2019 Oct;78(10):1333-1338. doi: 10.1136/annrheumdis-2019-215304. Epub 2019 Jun 13. Ann Rheum Dis. 2019. PMID: 31196844
Giant cell arteritis treatment patterns and rates of serious infections.
Tedeschi SK, Jin Y, Vine S, Lee H, Pethoe-Schramm A, Yau V, Kim SC. Tedeschi SK, et al. Among authors: pethoe schramm a. Clin Exp Rheumatol. 2022 May;40(4):826-833. doi: 10.55563/clinexprheumatol/uonz1p. Epub 2021 Dec 13. Clin Exp Rheumatol. 2022. PMID: 34905480 Free PMC article.